NYSE | WPI:

at |

 

Business Segments | Brand

Our Brand Division

The Watson Brand division brings diversification to our business mix through a portfolio of patented and off-patented trademarked products. This business develops, manufactures and markets its products through two core areas: our Specialty Products product line includes urology and a number of other non-promoted products, and our Nephrology product line, which is primarily marketed to nephrologists and dialysis centers, features products for the treatment of iron deficiency anemia. The Watson Brand division is integral to our Company’s long-term strategy for “balanced” growth.

Highlights

  • Focused on specialty physicians (urology and nephrology)
  • 27 pharmaceutical product families in the portfolio
  • Generated approximately $455 million in brand revenue during 2008
  • Accounted for 18% of total 2008 annual revenue at Watson

Key Brands

In Urology In Nephrology
RAPAFLO® (silodosin) capsules
A treatment for the signs and symptoms of benign prostatic hyperplasia
FERRLECIT® (sodium ferric gluconate complex in sucrose injection)
IV iron replacement therapy for certain patients with iron deficiency anemia
GELNIQUE® (oxybutynin chloride) 10% gel
A treatment for overactive bladder symptoms
INFeD® (iron dextran injection)
IV iron replacement therapy for certain patients with iron deficiency anemia
TRELSTAR® LA / TRELSTAR® DEPOT (triptorelin pamoate for injectable suspension)
A treatment for advanced prostate cancer symptoms

R&D Pipeline

  Indication/Therapeutic Target Market Phase I Phase II Phase III Submitted Approved Launched
TRELSTAR® (triptorelin pamoate for injectable suspension)
6-month formulation
Advanced Prostate Cancer/Urology U.S. filled filled filled half filled
Novel Oral Contraceptive
 
Prevention of Pregnancy U.S. filled filled half filled
URACYST® (sterile sodium chondroitin sulfate)
 
Interstitial cystitis U.S. filled half filled